Apogee Therapeutics, Inc.
APGE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $54 | $56 | $46 | $60 |
| G&A Expenses | $17 | $17 | $17 | $16 |
| SG&A Expenses | $17 | $17 | $17 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $71 | $73 | $63 | $76 |
| Operating Income | -$71 | -$73 | -$63 | -$76 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | $7 | $8 | $9 |
| Pre-Tax Income | -$65 | -$66 | -$55 | -$67 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$65 | -$66 | -$55 | -$67 |
| % Margin | – | – | – | – |
| EPS | -1.11 | -1.13 | -0.95 | -1.22 |
| % Growth | 1.8% | -18.9% | 22.1% | – |
| EPS Diluted | -1.11 | -1.13 | -0.95 | -1.22 |
| Weighted Avg Shares Out | 59 | 58 | 58 | 55 |
| Weighted Avg Shares Out Dil | 59 | 58 | 58 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $7 | $8 | $9 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$65 | -$73 | -$63 | -$76 |
| % Margin | – | – | – | – |